'Kidney Transplant Performed First'... Simultaneous Improvement in Aplastic Anemia and Renal Failure
Seoul St. Mary's Hospital Organ Transplant Center Publishes Treatment Strategy in the American Journal of Transplantation
All Four Patients with Both Aplastic Anemia and End-Stage Renal Failure Show Improvement
Hematologic Recovery Observed
The Organ Transplant Center at Seoul St. Mary's Hospital announced on March 30 that they observed clinical improvement by adopting a treatment strategy of performing kidney transplantation first in patients suffering from both severe aplastic anemia and end-stage renal failure. The related research was recently published in the international journal 'American Journal of Transplantation'.
From left: Jeong Byungha, Professor of Nephrology, Seoul St. Mary's Hospital; Silvia Park, Professor of Hematology, Seoul St. Mary's Hospital. Seoul St. Mary's Hospital
View original imageThe research team analyzed the treatment outcomes of four patients diagnosed with both conditions and explained that all patients showed stable recovery of kidney function along with significant hematologic improvement.
Severe aplastic anemia is a disease characterized by a general decrease in blood cells due to impaired bone marrow function, and hematopoietic stem cell transplantation is known as a curative treatment. For end-stage renal failure, kidney transplantation is the most effective therapy. The challenge arises when both conditions coexist, as there are no clear guidelines on the order of treatments, making clinical decision-making difficult.
Considering these limitations, the researchers chose a strategy of performing kidney transplantation first, followed by hematopoietic stem cell transplantation if necessary. All patients were transfusion-dependent, but after kidney transplantation, they experienced immediate recovery of graft kidney function and maintained stable outcomes for one year without acute rejection or major complications.
Among them, two patients received additional hematopoietic stem cell transplantation from the same donor about three months after kidney transplantation. These two patients maintained stable outcomes even after discontinuing immunosuppressive drugs. The medical team interpreted this as the possibility of immunologic remission due to the formation of donor chimerism.
The remaining two patients, even without receiving hematopoietic stem cell transplantation, gradually improved in anemia and thrombocytopenia and were able to overcome their transfusion-dependent state. Their bone marrow function also showed signs of recovery. The research team suggested that the combined effects of reduced uremic toxins after kidney transplantation, alleviation of inflammation, and the impact of immunosuppressants may have contributed to these results.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Jeong Byeongha, Professor of Nephrology at Seoul St. Mary's Hospital, who participated in the study, said, "The finding that hematologic recovery can be achieved with kidney transplantation alone in some patients is a clinically significant result." He added, "It is necessary to establish criteria for selecting suitable patient groups through systematic prospective studies in the future."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.